Quality assessment of nine paracetamol 500 mg tablet brands marketed in Saudi Arabia

Reem AlSwayeh¹, Syed N. Alvi¹ and Muhammad M. Hammami¹,²*

Abstract
Objective: To evaluate in-vitro quality of paracetamol 500 mg tablet brands marketed in Saudi Arabia. Results: Two reference (R1 and R2) and seven generic (G1-G7) brands were commercially available. Four brands were single-drug, containing paracetamol only (R1, G1-G3) and five contained additional active ingredients (R2, G4-G7). All brands were immediate-release. Weight variation \( (n = 20, \text{ range as percent difference from mean}) \), active substance content \( (n = 20, \text{ mean (SD) as percent difference from label}) \), breaking force \( (n = 10, \text{ mean (SD)}) \), and friability \( (n = 20, \text{ as percent weight loss}) \) ranged from 97 to 102%, 96.1% (2.9%) to 99.8% (1.1%), 9.9 (0.4) to 21.0 (0.9) kg, and 0.017% to 0.809%, respectively. Disintegration (water medium) time \( (n = 6, \text{ minute: second}) \) ranged from 02:35–03:09 to 12:49–13:10. Dissolution (phosphate buffer, pH 5.8) profile showed a mean release at 30 min of 87% to 97% of label content, with seven brands passing stage-1 \( (\geq 85\% \text{ for each of } 6 \text{ test units}) \) and two passing stage-2 \( (\text{mean of } 12 \text{ test units } \geq 85\%) \) criteria. Despite statistically significant differences between R1 and R2 and some of their corresponding generic brands in active substance content, breaking force, and amount dissolved at 30 min, all nine brands met the pre-specified quality standards.

Keywords: Paracetamol, Pharmaceutical quality, Saudi market, Dissolution profile, Generic brands, Reference brands, Combinational drugs

Introduction
The World Health Organization, among others, has continuously advocated the use of generic drug products because they expand healthcare accessibility [1]. However, lay people [2] and occasionally healthcare workers [3] not infrequently view local drug products as inferior to imported ones, questioning their quality and interchangeability.

Most countries, including Saudi Arabia, require that generic drug products pass standard in-vivo bioequivalence testing before marketing [4]. Although this should be assuring, ongoing evaluation of marketed products is critical to maintain trust. Performing such evaluation in-vitro is gaining regulatory support and has the advantages of saving money and time and of not requiring involvement of human research subjects [5–8].

Paracetamol (acetaminophen) is a cheap, widely used analgesic and antipyretic drug that is available over-the-counter [9]. It is commercially available for oral intake as immediate-release tablets of various strengths, alone or in combination with other active ingredients [10]. We previously reported the pharmaceutical quality of various diclofenac tablet formulations available on the Saudi market [11, 12]. The aim of this study was to evaluate in-vitro quality of paracetamol 500 mg tablet brands marketed in Saudi Arabia.

Main text
Drugs and chemicals
We assessed all single-drug and combinational brands of paracetamol 500 mg immediate-release tablet that were
commercially available in Riyadh, Saudi Arabia at the time of the study (September to December 2020). We were able to locate two reference (R1 and R2) brands and seven generic (G1-G7) brands. R1 and G1-G3 contained only paracetamol, while R2 and G4-G7 contained other active ingredients (caffeine, codeine, pseudoephedrine, or diphenhydramine). Label information of the studied brands is presented in Additional file 1: Table S1: Label information.

We purchased paracetamol (acetaminophen) reference standard from Sigma-Aldrich CO., Louis, MO., USA; HPLC grade methanol and acetonitrile from Fisher Scientific, Fair Lawn, NJ, USA; and sodium phosphate monobasic and sodium phosphate dibasic from Fisher Chemical, Fair Lawn, New Jersey, USA. HPLC grade water was prepared by reverse osmosis and was further purified by passing through a Milli-Q System (Millipore, Bedford, MA, USA).

**Instruments**

High performance liquid chromatography (HPLC)-dissolution system consisted of Waters 2690D Separation Module, Hanson Research SR8-Plus, United States Pharmacopoeia (USP) dissolution apparatus II (paddle), and Waters 996 photodiode array detector (Waters Associates Inc., Milford, MA, USA). Mettler AT20 sensitive balance was purchased from Mettler Toledo (Greifensee, Switzerland). Model SSE-731 Microprocessor Disintegration Test Apparatus, Model SSE-710 Microprocessor Friability Apparatus, and Model SSE-DIGIT AB-SPV Digital Tablet Hardness Tester were purchased from Sunshine Scientific Equipment, Delhi, India.

**Sample preparation & HPLC assay**

We prepared paracetamol stock solution in water and diluted it to produce standard curve samples of 40, 80, 160, 240, 320, 480, 560, and 700 µg/ml, and quality control samples of 40, 120, 350, and 630 µg/ml. A previously reported HPLC assay [13] was used to determine active substance content (ASC) and dissolution profiles. The assay uses Symmetry Shield RP18, 5 µm cartridge and a mobile phase composed of water, methanol, and acetonitrile (80:10:10, v: v: v), delivered at a flow rate of 0.9 ml/min. The analysis was performed under isocratic condition (column and sample compartment temperature 40 °C and 8 °C, respectively). The photodiode array detector was set at 245 nm. There was no interference from tablet’s excipients. We used a standard curve with eight non-zero points (40, 80, 160, 240, 320, 480, 560, 700 µg/ml) and three sets of four quality control samples (40, 120, 350, 630 µg/ml) in each run. Mean (SD) accuracy and coefficient of variation (n=9) were 103.6% (2.4%) and 5.3% (2.9%), 99.1% (5.0%) and 2.9% (1.8%), 99.6% (3.9%) and 3.5% (2.0%), and 102.3% (2.7%) and 3.0% (2.7%) for the four quality control samples, respectively.

**Quality control tests & calculations**

For weight variation, friability, and ASC tests 20 randomly-selected units of each brand were examined. For the weight variation test, we calculated mean (SD) and percent deviation of individual unit’s weight from mean weight of the brand. For the friability test, units were weighted, placed in a frabilator operated at 25 revolutions/minute for 4 min, then weighted again after dedusting. We determined friability as percent weight loss. For the ASC test, the units were individually crushed, dissolved in 100 ml water, filtered with a syringe using 0.2 µm filter, and diluted in water, and 20 µl were injected into the HPLC system. We calculated mean (SD) content and percent deviation of individual units from label.

For tablet breaking force test, 10 randomly-selected units of each brand were examined and mean (SD) pressure required to break each unit was determined.

Six randomly-selected units of each brand underwent disintegration testing. We placed the basket rack in a 1000 ml vessel containing 900 ml water (37 ± 2 °C). The basket rack moved 5–6 cm up and down (31 cycles/minute) with the test unit remaining 1.5 cm below liquid surface and 2.5 cm above beaker bottom. We determined range of disintegration time (time to no particle on the basket).

Eight randomly-selected units of each brand initially underwent dissolution testing. If one or more units failed, additional 4 units were examined. 900 ± 1% ml of phosphate buffer (pH 5.8) was used as dissolution medium. It was composed of 0.05 M sodium phosphate dibasic and 0.05 M sodium phosphate monobasic (50: 50, v: v). Temperature was maintained at 37 ± 0.5 °C using constant bath temperature. Stirring rate was 50 ± 1 rounds per minute (rpm) for 60 min and then the test ended with a stirring rate of 150 rpm for 15 min (“infinity”). One ml sample was withdrawn midway between dissolution medium surface and rotating blade top, ≥ 1 cm away from vessel wall, and was immediately replaced with fresh medium. The samples were withdrawn at 5, 10, 15, 20, 30, 40, 60, and 75 min. We kept the vessels covered, verified mixture temperature, and observed unit’s behavior throughout the test. We injected 20 µl of the one ml samples into the HPLC system. We determined mean (SD) amount released and percent of label ASC released, at each time point.

We compared ASC, breaking force, and amount dissolved at 30 min of R1 to G1, G2, and G3 (each contains paracetamol only) and of R2 to G4, G5, G6, and G7 (each contains paracetamol plus other active substances) using
unpaired t test. Two tailed p value < 0.05 was considered significant.

Results

Table 1 summarizes the main results of the study. Mean weight of the nine brands ranged from 553.2 (3.3) to 838.1 (10.5) mg. Weight range was within 97–102% of mean weight for each brands. Mean (SD) ASC ranged from 96.1% (2.9%) to 99.8.2% (1.1%). Both parameters were within the acceptable limits (±5% and 90–110%, respectively) for each brand. However, R1 ASC was significantly lower than G1 ASC (p = 0.0002) and G2 ASC (p = 0.03), and R2 ASC was significantly higher than G4 ASC (p = 0.0001).

Mean (SD) breaking force ranged from 9.9 (0.4) to 21.0 (0.9) kg. R1 breaking force was significantly lower than G2 breaking force (p = 0.0001) and significantly higher than G3 breaking force (p = 0.0001). On the other hand, R2 breaking force was significantly higher than G4 breaking force (p = 0.0001) and significantly lower than G5 breaking force (p = 0.0001) and G7 breaking force (p = 0.0001). Weight loss due to friability ranged from 0.017% to 0.809%, which is within the acceptable limit of ±5%.

Disintegration time was variable. It ranged from 02:35 to 03:09 min: second for G1 to 12:49 to 13:10 min: second for G7. Nevertheless, all integration times were within the acceptable limit of ≤15 min.

Dissolution profiles of R1, R2 and G1-G7 are shown in Fig. 1. Each of the 8 units of all brands except G4 and G7 released ≥ 85% (Q (80%)+ 5%) of label ASC within 30 min and thus met the acceptance criteria of stage-1 (≥ 85% release from each of 6 test units). [14] However, because 4 and 1 of the 8 units of G4 and G7, respectively, released < 85% of label ASC by 30 min (80–84% and 82%, respectively), an additional 4 units were tested for each brand. Mean percent release for 12 units of G4 and G7 was 87% and 96%, respectively, meeting the acceptance criteria of stage-2 (mean release of 12 test units ≥ 85%) [14]. During dissolution, we did not observe any artifact such as coning, gumming, capping, sticking, etc. for any of the brands. Interestingly, amount dissolved at 30 min was significantly higher for R1 compared to G1 (mean (95% confidence interval), 29.2 (23.2 to 35.2) mg, p = 0.0001) and G2 (mean difference 10.1 (4.0 to 16.2 mg, p = 0.003). Amount dissolved at 30 min was also significantly higher for R2 compared to G4 (mean difference 40.8 (22.7 to 58.9) mg, p = 0.0002).

Discussion

We assessed the pharmaceutical quality of 2 reference and seven generic paracetamol 500 mg immediate-release tablet brands that were commercially available on the Saudi market at the time of the study. All brands passed in-vitro quality testing according to USP [15]. Namely, weight variation of ±5% from mean weight (since tablet weight was ≥ 250 mg); mean ASC between 90–110% of label; ≤1% weight loss due to friability; complete disintegration in water within 15 min; and release of ≥85% within 30 min in phosphate buffer (pH 5.8).

The reported quality of paracetamol tablets on other markets is variable [16–18]. As examples, Zaid et al. evaluated the quality of 10 paracetamol products on the Palestinian market and concluded that generic products are often in-vitro comparable to the innovator product [16]. Similar conclusion was reached by Ukwueze et al. after studying six brands of paracetamol generic formulations marketed in Nigeria [17]. However, in a study from
Malawi, out of 11 paracetamol brands, one failed ASC testing, and three failed friability testing [18]. The current results together with the results of in-vitro quality studies of drug products containing other active ingredients, [11, 12] in-vivo pre-marketing studies [19–26], and in-vivo post-marketing study [27] provide assurance of the quality of generic drug products commercially available in Saudi Arabia.

**Study strengths**

The study assessed all commercially available brands, included two reference brands, examined multiple-point dissolution curves, and used a validated HPLC assay.

**Study limitations**

Our results do not apply to other paracetamol 500 mg tablet brands that are listed on the Saudi formulary but were not commercially available at the time of the study. Further, our results do not apply to paracetamol formulations of other strength or form. Furthermore, the specific variations in manufacturing procedures that led to the observed differences among the different brands were not addressed in this study.

**Abbreviations**

ASC: Active substance content; G: Generic brand; HPLC: High performance liquid chromatography; R: Reference brand; rpm: Rounds per minute; SD: Standard deviation; USP: United States Pharmacopoeia.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13104-021-05672-y.

**Additional file 1: Table S1.** Label information of two reference and seven generic paracetamol 500 mg tablet brands available on the Saudi market.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

MHW designed the study, performed data analysis, and wrote the manuscript. RAS and SNA performed the experiments, co-analyzed data, and critically reviewed the manuscript. All authors agree to be accountable for all aspects of the work and approved the final version of the manuscript. All authors read and approved the final manuscript.
Funding
Not applicable.

Availability of data and materials
Additional data are available in Additional file 1: Table S1. Label information. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was conducted after approval of the Research Advisory Council of the King Faisal Specialist Hospital and Research Centre. The study did not involve human or animal subjects.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Clinical Studies and Empirical Ethics Department, King Faisal Specialist Hospital and Research Centre, P O Box # 3354 (MBC 03), Riyadh 11211, Saudi Arabia.
2Alfaisal University College of Medicine, Riyadh, Saudi Arabia.

Received: 10 December 2020   Accepted: 24 June 2021

Published online: 30 June 2021

References
1. Anonymous (2015). Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. WHO Regional Office for Europe. https://apps.who.int/iris/handle/10665/159405. Accessed 12 Dec 2020.
2. Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Med. 2015;13:173. https://doi.org/10.1186/s12916-014-0145-3.
3. Toverud E-L, Hartmann K, Håkonsen H. A systematic review of physicians’ and pharmacists’ perspectives on generic drug use: what are the global challenges? Appl Health Econ Health Policy. 2015;13(Suppl 1):35–45. https://doi.org/10.1007/s40258-014-0145-2.
4. Saudi Food and Drug Authority. https://old.sfda.gov.sa/en/pages/default.aspx. Accessed 12 Dec 2020.
5. Anand Q, Yu LX, Conner DP, Davit BM. Dissolution testing for generic drugs: an FDA perspective. AAPS J. 2011;13(3):328–35. https://doi.org/10.1208/s12248-011-9272-y.
6. FDA Center for Drug Evaluation and Research. Guidance for the industry: dissolution testing of immediate release solid oral dosage forms. Rockville, MD, 1997. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dissolution-testing-immediate-release-solid-oral-dosage-forms. Accessed 12 Dec 2020.
7. EMA Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence. London, UK, 2010. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 12 Dec 2020.
8. WHO Technical Report Series. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. 2006. No. 937. https://www.who.int/medicines/services/experience/committees/pharmprep/QAS04_093Rev4_final.pdf. Accessed 12 Dec 2020.
9. Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S. Paracetamol: new vistas of an old drug. CNS Drug Rev. 2006;12(3–4):250–75.
10. Saudi Food & Drug Authority. Drug list. https://www.sfda.gov.sa/en/drugs-list. Accessed 12 Dec 2020.
11. Hammami MM, AlSwayeh R, Alvi SN. Eight enteric-coated 50 mg diclofenac sodium tablet formulations marketed in Saudi Arabia: in-vitro quality evaluation. BMC Res. Notes. 2020;13:428. https://doi.org/10.1186/s13104-020-05270-4.
12. Hammami MM, AlSwayeh R, Hussein RF. Pharmaceutical quality of seven brands of diclofenac tablet on the Saudi market. BMC Res. Notes. 2020;13:548. https://doi.org/10.1186/s13104-020-05385-8.
13. AlSwayeh R, Alvi SN, Hammami MM. Rapid determination of acetaminophen levels in human plasma by high performance liquid chromatography. J Pharmtech Res. 2016;6(3):710–9.
14. The International Pharmacopoeia, Ninth Edition (2019). https://apps.who.int/phint/en/p/docf/. Accessed 12 Dec 2020.
15. Pharmacopoeia online. USP32. http://www.usp32p.eu/usp32/pub/data/v32270/usp32nf27o_m200.html. Accessed 12 Dec 2020.
16. Zaid A, Rinno T, Jaradat N, Jodeh S, Khammash S. Interchangeability between paracetamol tablets marketed in Palestine. Is there a quality reason for a higher price? EMHJ. 2013;19(6):542–6.
17. Ukwueze SE, Uzochukwu IC, Ngonebu EJ. Comparative quality assessment and in vitro dissolution profile of some paracetamol tablet generics marketed in Nigeria. Port Harcourt Med J. 2008;385–90.
18. Khuluza F. In vitro evaluation of the quality of paracetamol and cotrimoxazole tablets used in Malawi based on pharmaceutical standards. Malawi Med J. 2014;26(2):38–41.
19. Lockyer M, Al-Dgither S, AlGaii E, Yusuf A, Hammami MM. Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers. Biopharm Drug Dispos. 2005;26(3):117–20.
20. Lockyer M, Al-Dgither S, AlGaii E, Hammami MM. Bioequivalence of two oral formulations of gatifloxacin tablets in healthy male volunteers. J Appl Res. 2005;5(1):73–9.
21. AlGaii E, Lockyer M, Al-Dgither S, Hammami MM. Bioequivalence evaluation of two formulations of fluconazole 150 mg capsules in healthy Arab men. Biopharm Drug Dispos. 2005;26(4):143–6.
22. AlGaii E, Al-Dgither S, Lockyer M, Hammami MM. Bioequivalence study of two amoxicillin formulations. Drug Research. 2006;56(1):48–55.
23. Yusuf A, Al Gaii E, Hammami MM. Bioequivalence evaluation of two rosiglitazone tablet formulations. Drug Research. 2006;56(11):740–3.
24. Yusuf A, Al Gaii E, Hammami MM. Bioequivalence assessment of two domperidone tablet formulations. Drug Research. 2007;57:269–73.
25. Hussein RF, Lockyer M, Hammami MM. Bioequivalence assessment of two capsule formulations of meperazine in healthy volunteers. Drug Res. 2007;57(2):101–5.
26. Alhawari S, AlGaii E, Yusuf A, Abdelgaleel A, Hammami MM. Bioequivalence study of two metformin tablet formulations. Drug Res. 2007;57(4):192–5.
27. Hammami MM, De Padua SJS, Hussein R, Al Gaii E, Khodr NA, Al-Swayeh R, Alvi SN, Binhashim N. Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs. BMC Pharmacol Toxicol. 2017;18:78. https://doi.org/10.1186/s40360-017-0182-1.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.